Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

March 31, 2014

Study Completion Date

June 30, 2014

Conditions
Liver Disease
Interventions
DRUG

Metformin

Patients with Steatohepatitis treated with diet, exercise and metformin

DIETARY_SUPPLEMENT

Siliphos+ Selenium - Methionine + Alpha Lipoic Acid

Patients with Steatohepatitis treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID

DIETARY_SUPPLEMENT

Siliphos+ Selenium - Methionine + Alpha Lipoic Acid

Patients with fatty liver treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID

DRUG

Metformin

Patients with fatty liver treated with diet, exercise and metformin

Trial Locations (1)

14000

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City

All Listed Sponsors
lead

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

OTHER

NCT01650181 - Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis | Biotech Hunter | Biotech Hunter